Medline drops 3.9% as large sponsor secondary and margin concerns weigh on sentiment

Medline Inc. (MDLN) is down 3.9% today. Here is some analysis on what might have caused this price movement.

Analysis: The move appears tied to continued selling pressure after a large, sponsor-led secondary offering priced at $37, which can act as a near-term “supply overhang” even when the company receives no proceeds. Investors have also been focused on recent margin and profit pressure discussed in the company’s latest quarterly results and SEC filing, including higher costs related to tariffs and investments to support growth.

Details:

Medline closed an upsized secondary offering of 72,554,594 Class A shares at $37.00 per share, sold by existing large shareholders rather than the company.

Medline also announced the pricing of that upsized secondary at $37.00 per share ahead of closing, highlighting the scale of the block coming to market.

In its first-quarter 2026 results, Medline reported higher costs (including tariff impacts) alongside lower net income versus the prior-year quarter despite sales growth.

In its quarterly SEC filing, Medline described a year-over-year gross margin decline and cited higher import costs due to tariffs as a driver.

Sources:

Medline Newsroom, U.S. Securities and Exchange Commission, GlobeNewswire

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$MDLN Insider Trading Activity

$MDLN insiders have traded $MDLN stock on the open market 28 times in the past 6 months. Of those trades, 4 have been purchases and 24 have been sales.

Here’s a breakdown of recent trading of $MDLN stock by insiders over the last 6 months:

GROUP INC. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
MOZART COINVESTMENT HOLDINGS, L.P. CARLYLE has made 0 purchases and 2 sales selling 45,242,173 shares for an estimated $1,625,293,097.
& FRIEDMAN CAPITAL PARTNERS X (PARALLEL), L.P. HELLMAN has made 0 purchases and 7 sales selling 32,219,608 shares for an estimated $1,231,240,883.
8 HOLDINGS MOZART MANAGER L.L.C. BCP has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
MOZART ML-2 HOLDCO L.P. BX has made 0 purchases and 4 sales selling 27,852,986 shares for an estimated $1,128,268,756.
GROUP CAYMAN INVESTMENT HOLDINGS, L.P. TC sold 26,105,840 shares for an estimated $1,070,339,440
CIRCLE ML HOLDCO GP, LLC CP sold 26,105,840 shares for an estimated $1,070,339,440
PRIVATE LTD GIC has made 1 purchase buying 12,586,206 shares for an estimated $364,999,974 and 1 sale selling 10,204,351 shares for an estimated $289,480,090.
GROUP VII S1, L.L.C. TC sold 19,136,333 shares for an estimated $554,953,657
AGGREGATOR II LP MOZART sold 13,462,600 shares for an estimated $381,911,075
ANDREW J. MILLS purchased 2,586,206 shares for an estimated $74,999,974
CHARLES N. MILLS has made 2 purchases buying 2,579,310 shares for an estimated $74,799,990 and 0 sales.

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive MDLN Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$MDLN Hedge Fund Activity

We have seen 259 institutional investors add shares of $MDLN stock to their portfolio, and 62 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

CARLYLE GROUP INC. added 215,303,036 shares (+inf%) to their portfolio in Q4 2025, for an estimated $9,042,727,512
VANGUARD GROUP INC added 18,887,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $793,277,856
H&F CORPORATE INVESTORS X, LTD. removed 13,040,572 shares (-13.1%) from their portfolio in Q1 2026, for an estimated $580,305,454
JANUS HENDERSON GROUP PLC added 10,564,621 shares (+inf%) to their portfolio in Q4 2025, for an estimated $443,714,082
BAILLIE GIFFORD & CO added 10,410,371 shares (+inf%) to their portfolio in Q4 2025, for an estimated $437,235,582
FMR LLC added 10,201,987 shares (+38.7%) to their portfolio in Q1 2026, for an estimated $453,988,421
CAPITAL RESEARCH GLOBAL INVESTORS added 8,377,467 shares (+56.7%) to their portfolio in Q1 2026, for an estimated $372,797,281

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$MDLN Analyst Ratings

Wall Street analysts have issued reports on $MDLN in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Tigress Financial issued a "Buy" rating on 05/13/2026
BTIG issued a "Buy" rating on 01/12/2026
RBC Capital issued a "Outperform" rating on 01/12/2026
Bernstein issued a "Outperform" rating on 01/12/2026
Wolfe Research issued a "Outperform" rating on 01/12/2026
Barclays issued a "Overweight" rating on 01/12/2026
Citigroup issued a "Buy" rating on 01/12/2026

To track analyst ratings and price targets for $MDLN, check out Quiver Quantitative's $MDLN forecast page.

$MDLN Price Targets

Multiple analysts have issued price targets for $MDLN recently. We have seen 24 analysts offer price targets for $MDLN in the last 6 months, with a median target of $50.0.

Here are some recent targets:

Navann Ty from BNP Paribas set a target price of $40.0 on 05/14/2026
Ivan Feinseth from Tigress Financial set a target price of $62.0 on 05/13/2026
David Larsen from BTIG set a target price of $55.0 on 05/07/2026
Lee Hambright from Bernstein set a target price of $54.0 on 05/07/2026
Patrick Donnelly from Citigroup set a target price of $55.0 on 05/07/2026
Lisa Gill from JP Morgan set a target price of $53.0 on 03/10/2026
Patrick Wood from Morgan Stanley set a target price of $52.0 on 03/02/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.